Last reviewed · How we verify

NCT06961604

A Novel Method for Determination of Thromboembolic Stroke Origin

Not yet recruiting EARLY_PHASE1 Last updated 8 May 2025
What this trial tests

EARLY_PHASE1 trial testing NaF PET-CT in Thromboembolic Stroke in 20 participants. Not yet recruiting.

Timeline
1 June 2025
Primary endpoint
1 June 2025
31 May 2026

Quick facts

Lead sponsorAtlantic Health System
PhaseEARLY_PHASE1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment20
Start date1 June 2025
Primary completion1 June 2025
Estimated completion31 May 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Atlantic Health System — full company profile →

Who can join

18 and older, any sex, with Thromboembolic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Atlantic Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06961604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing